Cargando…
Emerging Immunotherapy for Acute Myeloid Leukemia
Several immune checkpoint molecules and immune targets in leukemic cells have been investigated. Recent studies have suggested the potential clinical benefits of immuno-oncology (IO) therapy against acute myeloid leukemia (AML), especially targeting CD33, CD123, and CLL-1, as well as immune checkpoi...
Autores principales: | Tabata, Rikako, Chi, SungGi, Yuda, Junichiro, Minami, Yosuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920435/ https://www.ncbi.nlm.nih.gov/pubmed/33669431 http://dx.doi.org/10.3390/ijms22041944 |
Ejemplares similares
-
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
por: Ikeda, Daisuke, et al.
Publicado: (2022) -
The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia
por: Urabe, Akiko, et al.
Publicado: (2023) -
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020) -
Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
por: Arai, Hironori, et al.
Publicado: (2022) -
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
por: Chi, Sung-Gi, et al.
Publicado: (2022)